Cargando…

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine

Preventive subcutaneous treatment of severe hemophilia A with bispecific antibodies that mimic the action of coagulation factor VIII (FVIII) is emerging as an effective alternative to replacement therapy with intravenous administration of FVIII concentrates, either derived from plasma or produced by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hermans, Cedric, Pierce, Glenn F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Forum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394560/ https://www.ncbi.nlm.nih.gov/pubmed/37538493 http://dx.doi.org/10.1016/j.rpth.2023.100173

Ejemplares similares

Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?
por: Krumb, Evelien, et al.
Publicado: (2021)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
por: Sampei, Zenjiro, et al.
Publicado: (2013)

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays
por: Adamkewicz, Joanne I., et al.
Publicado: (2019)

Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia
por: Krumb, Evelien, et al.
Publicado: (2021)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
por: McEneny-King, Alanna, et al.
Publicado: (2017)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
por: Shima, Midori
Publicado: (2020)

Direct-to-consumer Marketing to People with Hemophilia
por: Kucab, Philip, et al.
Publicado: (2016)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Inspired, but not mimicking: a conversation between artificial intelligence and human intelligence
por: Zhao, Weijie
Publicado: (2022)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center
por: Yoo, Ki Young, et al.
Publicado: (2016)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Ten Years on: Generating Innovative Responses to Avian Influenza
por: Forster, Paul
Publicado: (2013)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity
por: Sampei, Zenjiro, et al.
Publicado: (2014)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Surgically assisted caudal anesthesia in a case of Ankylosing Spondylitis—An innovative approach
por: Radhashyam, Paria, et al.
Publicado: (2019)

A forum on innovative fusion approaches: will there be a SpaceX for fusion energy?
por: Zhao, Weijie
Publicado: (2019)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
por: Lieuw, Kenneth
Publicado: (2017)

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
por: Mahmoud Abu Arra, Caesar, et al.
Publicado: (2020)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

General Internal Medicine and Specialty Medicine – Time to Rethink the Relationship
por: Rhodes, Jonathan M, et al.
Publicado: (1999)

AtEXT3 is not essential for early embryogenesis or plant viability in Arabidopsis
por: Doll, Nicolas Max, et al.
Publicado: (2022)

Essential or dismissible? Exploring the challenges of waste pickers in relation to COVID-19
por: Carenbauer, Mary Greene
Publicado: (2021)

Negative pressure aerosol containment box: An innovation to reduce COVID-19 infection risk in healthcare workers
por: Gupta, Vivek, et al.
Publicado: (2020)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
por: Chen, Alex C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_co0st31tgcp9j1l7ikpjf3vfjp